IVA Inventiva SA

Inventiva reçoit le statut de « Breakthrough Therapy » de la part de la FDA pour lanifibranor, son principal candidat médicament dans la NASH

Inventiva reçoit le statut de « Breakthrough Therapy » de la part de la FDA pour lanifibranor, son principal candidat médicament dans la NASH
EN
12/10/2020

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

Free Trial
IVA INVENTIVA SA

Inventiva: 1 director

A director at Inventiva bought 24,700 shares at 3.295EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

10/24/25 October 24, 2025 1 EN
Guy Sips ... (+6)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Hoste
HEIA HEINEKEN NV
PROX Proximus SA de ... ... (+9)

Morning Notes : ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PRO...

: ABI BB, ASML NA, BAR BB, OPTI BB, HEIA NA, IVA FP, PROX BB, SEQUA BB, MRUS US

HEIA HEINEKEN NV
PROX PROXIMUS SA DE DROIT PUBLIC
OPTI CRESCENT
ABI ANHEUSER-BUSCH INBEV SA/NV
MRUS MERUS B V
IVA INVENTIVA SA
ASML ASML HOLDING NV
SEQUA SEQUANA MEDICAL
BAR BARCO NV
10/15/25 October 15, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva Announces the Implementation of a New ATM Program

Inventiva Announces the Implementation of a New ATM Program Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) has filed today a shelf registration statement on Form F-3 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”). The Registration Statement includes a base prospectus and a sales agreement ...

October 14, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva annonce la mise en place d’un nouveau programme « At-The-Mar...

Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM) Daix (France), New York City (New York, Etats-Unis), le 14 octobre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce ce jour avoir enregistré un document préalable  intitulé « Form F-3 » (le « Document d’Enregistrement »), auprès de la U.S. Securities and Exchange Commission (« SEC »), aux Etats...

October 14, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Thibault Leneeuw
  • Wim Lewi
FAGR FAGRON SA
SOF SOFINA SA
IVA INVENTIVA SA
ENRGY ENERGYVISION
10/09/25 October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch